Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II

被引:25
|
作者
Gong, Yanjun [1 ]
Li, Xuan [2 ]
Ma, Xiang [3 ]
Yu, Hongwei [4 ]
Li, Ying [5 ]
Chen, Jiyan [6 ]
Zhang, Guochun [7 ]
Wang, Bin [8 ]
Qi, Xiaoyong [9 ]
Meng, Haiyan [10 ]
Wang, Xiaofeng [11 ]
Mu, Jianjun [12 ]
Hu, Xitian [13 ]
Wang, Jingping [14 ]
Liu, Shaowen [15 ]
Liu, Gang [16 ]
Yang, Zhenyu [17 ]
Zhou, Yujie [18 ]
Kong, Xiangqing [19 ]
Yan, Yuhu [20 ]
Wang, Changqian [21 ]
Wang, Jian' An [22 ]
Wang, Lijun [23 ]
Fu, Guosheng [24 ]
Wei, Lin [25 ]
Peng, Daoquan [26 ]
Zhang, Shuyang [27 ]
Li, Ruogu [28 ]
Mao, Anhua [29 ]
Bian, Rui [29 ]
Tang, Wenmin [29 ]
Ran, Yuqin [29 ]
Jiang, Jie [1 ]
Huo, Yong [1 ]
机构
[1] Peking Univ First Hosp, Dept Cardiol, Beijing 100034, Peoples R China
[2] Jinqiu Hosp Liaoning Prov, Dept Cardiol, Shenyang, Peoples R China
[3] Xinjiang Med Univ, Affiliated Hosp 1, Dept Cardiol, Urumqi, Peoples R China
[4] Zhengzhou First Peoples Hosp, Dept Cardiol, Zhengzhou, Peoples R China
[5] Shanghai East Hosp, Dept Cardiol, Shanghai, Peoples R China
[6] Guangdong Prov Peoples Hosp, Dept Cardiol, Guangzhou, Peoples R China
[7] Second Hosp Harbin, Dept Cardiol, Harbin, Peoples R China
[8] Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Cardiol, Shantou, Peoples R China
[9] Hebei Gen Hosp, Dept Cardiol, Shijiazhuang, Hebei, Peoples R China
[10] Shandong Prov Third Hosp, Dept Rehabil, Jinan, Peoples R China
[11] Tradit Chinese Med Hosp Xinjiang Uygur Autonomous, Dept Cardiol, Urumqi, Peoples R China
[12] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiol, Xian, Peoples R China
[13] Shijiazhuang First Hosp, Dept Cardiol, Shijiazhuang, Hebei, Peoples R China
[14] Cardiovasc Hosp Shanxi Prov, Dept Cardiol, Taiyuan, Peoples R China
[15] Shanghai Gen Hosp, Dept Cardiol, Shanghai, Peoples R China
[16] Hebei Med Univ, Hosp 1, Dept Cardiol, Shijiazhuang, Hebei, Peoples R China
[17] Wuxi Peoples Hosp, Dept Cardiol, Wuxi, Jiangsu, Peoples R China
[18] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China
[19] Jiangsu Prov Hosp, Dept Cardiol, Nanjing, Peoples R China
[20] Jinzhong First Peoples Hosp, Dept Cardiol, Jinzhong, Peoples R China
[21] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Cardiol, Shanghai, Peoples R China
[22] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Cardiol, Hangzhou, Peoples R China
[23] Shijiazhuang Third Hosp, Dept Cardiol, Shijiazhuang, Hebei, Peoples R China
[24] Zhejiang Univ, Sch Med, Sir Run Shaw Hosp, Dept Cardiol, Hangzhou, Peoples R China
[25] First Hosp Harbin, Dept Cardiol, Harbin, Peoples R China
[26] Cent South Univ, Xiangya Hosp 2, Dept Cardiol, Changsha, Peoples R China
[27] Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China
[28] Shanghai Chest Hosp, Dept Cardiol, Shanghai, Peoples R China
[29] MSD China, Global Med & Sci Affairs GMSA, Shanghai, Peoples R China
关键词
acute coronary syndrome; DYSIS II; LDL-C goal; lipid-lowering therapy; statin; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR OUTCOMES; LDL CHOLESTEROL; GLOBAL REGISTRY; STATIN THERAPY; GUIDELINES; MANAGEMENT; DISEASE; HYPERCHOLESTEROLEMIA; METAANALYSIS;
D O I
10.1002/clc.23725
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Dyslipidemia International Study II (DYSIS II)-China was conducted to determine the low-density lipoprotein cholesterol (LDL-C) goal (<1.8 mmol/L) attainment rate in patients with post-acute coronary syndrome (ACS). Hypothesis Compliance with treatment guideline recommendations improves the LDL-C goal attainment rate in post-ACS patients. Methods This multicenter prospective observational study conducted at 28 tertiary hospitals determined the LDL-C goal attainment rates at admission and 6-month follow-up in patients on lipid-lowering treatment (LLT) for >= 3 months and those not on LLT (LLT-naive or off LLT for >= 3 months) at admission. Predictors of goal attainment at 6 months were identified using multivariate logistic regression. Results The LDL-C goal attainment rate at admission in 1102/1103 enrolled patients was 17.1%; it was 41.2% among 752 patients with available lipid results at 6 months. The distance to goal was 0.7 mmol/L at 6 months. Statin monotherapy was the most prescribed LLT. Only 7.7% of patients were receiving statin + ezetimibe and 8.4% of patients were receiving an atorvastatin-equivalent dose of >= 40 mg/day at 6 months. Being male (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.1-2.6) and undergoing percutaneous coronary intervention during index hospitalization (OR 1.5, 95% CI 1.1 to 2.1) were the independent predictors for LDL-C goal attainment. Conclusions This real-world DYSIS II study in China reports a low LDL-C goal attainment rate in post-ACS patients even after 6 months of LLT. Lack of intensification of statin therapy and underutilization of combinations suggest gaps between real-world treatment practices and guideline recommendations.
引用
收藏
页码:1575 / 1585
页数:11
相关论文
共 50 条
  • [41] Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)
    Matsuhisa, Munehide
    Odawara, Masato
    Hirose, Takahisa
    Koshida, Ryusuke
    Senda, Masayuki
    Tanaka, Yasushi
    Terauchi, Yasuo
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (02) : 249 - 256
  • [42] Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders Results From a 12-month, Real-World Study
    Zhang, Jian-Ping
    Weiss, Jeffrey J.
    McCardle, Melissa
    Klopchin, Hope
    Rosendahl, Eileen
    Maayan, Lawrence
    Convit, Antonio
    Kane, John M.
    Manu, Peter
    Correll, Christoph U.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (04) : 458 - 464
  • [43] Effectiveness and Safety of Tenofovir Alafenamide in Treatment-Naive and Treatment-Experienced Patients with Chronic Hepatitis B: Results of a Real-World Study from China
    Li, Lan-Qing
    Wang, Fa-Da
    Zhou, Jing
    Wang, Meng-Lan
    Tao, Yachao
    Chen, En-Qiang
    HEPATITIS MONTHLY, 2023, 23 (01)
  • [44] Psychosocial Functioning in Patients with Schizophrenia Treated with Aripiprazole - an Office-based Real-world Setting. Results from the German Post-marketing Surveillance Study
    Bergmann, F.
    Zacher, A.
    Nass, A.
    Urban, R.
    Werner, C.
    Spevakne-Gorocs, T.
    Kungel, M.
    Ebrecht, M.
    Modell, S.
    PHARMACOPSYCHIATRY, 2009, 42 (03) : 101 - 108
  • [45] Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan
    Hosono, Kumiko
    Matsumoto, Kazuko
    Shimbo, Miki
    Tsumiyama, Isao
    Kato, Chihiro
    MODERN RHEUMATOLOGY, 2023, 33 (02) : 381 - 391
  • [46] Impact of extended dual antiplatelet therapy on long-term prognosis in patients with acute coronary syndrome complicated with anemia: A sub-analysis of the real-world OPT-CAD study
    Zhao, Yu
    Li, Jing
    Ma, Sicong
    Jiang, Zaixin
    Li, Zhiguo
    Wang, Xiaozeng
    Han, Yaling
    Li, Yi
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2021, 98 (02) : E235 - E242
  • [47] Real-World Clinical Outcomes of IN.PACT Admiral Drug-Coated Balloon for Femoropopliteal Artery Disease-12-Month Results From Japan Post-Market Surveillance Study-
    Soga, Yoshimitsu
    Iida, Osamu
    Fujihara, Masahiko
    Kawasaki, Daizo
    Saito, Shigeru
    Urasawa, Kazushi
    Yokoi, Hiroyoshi
    Fernandez, Eric J.
    Guo, Jia
    Nakamura, Masato
    CIRCULATION JOURNAL, 2021, 85 (12) : 2149 - +
  • [48] Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
    Schwaner, Ingo
    Kuhn, Thomas
    Losem, Christoph
    Wolff, Thomas
    Otremba, Burkhard
    Zaiss, Matthias
    Huelsenbeck, Johannes
    Famulla, Kirsten
    Noesslinger, Thomas
    Rossi, Davide
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 2013 - 2020
  • [49] Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China
    Zhang, Yi
    Shi, Xiu-Jin
    Peng, Wen-Xing
    Han, Jia-Lun
    Lin, Bai-Di
    Zhang, Ru
    Zhang, Yun-Nan
    Yan, Jia-Lin
    Wei, Juan-Juan
    Wang, Yi-Fan
    Chen, Su-Wei
    Nan, Nan
    Fang, Zhen-Wei
    Zeng, Yong
    Lin, Yang
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [50] Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT)
    Utsunomiya, Kazunori
    Koshida, Ryusuke
    Kakiuchi, Seigo
    Senda, Masayuki
    Fujii, Shoko
    Kurihara, Yuji
    Gunji, Ryoji
    Kaku, Kohei
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (02) : 184 - 199